Hypertension Diagnostics, Inc. (HDII) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHypertension Diagnostics, Inc. (HDII) trades at $0.0001. Hypertension Diagnostics, Inc. (HDII) specializes in innovative, non-invasive medical technologies aimed at assessing arterial elasticity, crucial for cardiovascular health. Sector: Financials.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for HDII: HDII does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Hypertension Diagnostics, Inc. (HDII) Financial Services Profile
Hypertension Diagnostics, Inc. (HDII) is a pioneering company in the medical diagnostics sector, focusing on non-invasive technologies that assess arterial elasticity, a critical factor in cardiovascular health, catering to a wide range of healthcare professionals and researchers.
What Is the Investment Thesis for HDII?
Hypertension Diagnostics, Inc. (HDII) presents a unique investment thesis driven by its innovative product offerings in the medical diagnostics sector. The company's flagship products, the CVProfilor DO-2020 and MD-3000, target the growing need for non-invasive cardiovascular assessments, a market projected to expand as awareness of cardiovascular diseases rises. With a focus on arterial elasticity, HDII's technologies provide critical insights that can enhance patient outcomes, positioning the company well within the healthcare landscape. As the global market for cardiovascular diagnostics is expected to grow significantly, HDII's ability to capture market share will be a key driver of revenue. However, investors should remain cognizant of the risks associated with operating in the OTC market, including limited regulatory oversight and potential liquidity challenges. The company’s financial performance will be closely tied to its ability to commercialize its products effectively and navigate the competitive landscape.
Based on FMP financials and quantitative analysis
HDII Key Highlights
Market Cap: $0.00B, indicating a potential for growth in a niche market.
- Beta: -53.23, suggesting unusual volatility which may present risks and opportunities.
- No dividend yield, reflecting a focus on reinvestment in product development.
- Employee count of 3, indicating a lean operational structure.
- Established in 1988, showcasing a long history in the medical diagnostics sector.
Who Are HDII's Competitors?
HDII is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CIIT Tianci International, Inc. | $2.58 | +4.03% | 32 5-pillar | |
| COLA Columbus Acquisition Corp | $2.86 | -60.82% | $12.9M | 44 5-pillar |
| ASPC A SPAC III Acquisition Corp. | $10.81 | -0.16% | $25.3M | 47 5-pillar |
| RIBB Ribbon Acquisition Corp | $7.40 | -7.04% | $37.1M | 42 5-pillar |
| BKHA Black Hawk Acquisition Corporation | $12.28 | -0.81% | $51.0M | 47 5-pillar |
| IBAC IB Acquisition Corp. | $10.88 | -0.18% | $54.5M | 43 5-pillar |
| FVN Future Vision II Acquisition Corp. | $8.87 | +10.81% | $66.9M | 42 5-pillar |
| CPBI Central Plains Bancshares, Inc. | $19.75 | -1.62% | $82.6M | 73 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HDII's Key Strengths?
Innovative product offerings that address critical healthcare needs.
- Established presence in the medical diagnostics field since 1988.
- Strong focus on research and development to enhance product capabilities.
- Specialized knowledge in non-invasive cardiovascular diagnostics.
What Are HDII's Weaknesses?
Limited employee base may restrict operational capacity.
- No current dividend yield, which may deter income-focused investors.
- Operating in the OTC market may lead to liquidity challenges.
- Dependence on a narrow product line could pose risks if market dynamics shift.
What Are the Key Risks for HDII?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles that could delay product launches.
- Competition from established players in the medical diagnostics sector.
- Economic downturns affecting healthcare spending.
- Challenges in maintaining product quality and innovation.
What Threats Does HDII Face?
- Intense competition in the medical diagnostics sector.
- Regulatory challenges associated with medical device approvals.
- Market volatility due to economic fluctuations affecting healthcare spending.
- Potential technological advancements by competitors could outpace HDII's offerings.
What Are HDII's Competitive Advantages?
- Innovative technology that provides non-invasive assessments, a critical need in cardiovascular diagnostics.
- Established reputation in the medical diagnostics sector since 1988.
- Specialization in arterial elasticity, a niche area with limited competition.
- Strong relationships with healthcare providers and research institutions.
- Ability to generate comprehensive reports that assist in clinical decision-making.
What Does HDII Do?
Hypertension Diagnostics, Inc. (HDII), founded in 1988, is headquartered in Richmond Hill, Canada. The company is dedicated to designing, developing, manufacturing, and commercializing innovative, non-invasive medical technologies that assess arterial elasticity. This is particularly significant as small artery elasticity serves as an early indicator of cardiovascular disease. The cornerstone of HDII's product offerings is the CVProfilor system, which includes the CVProfilor DO-2020 and CVProfilor MD-3000. The DO-2020 provides essential indices for arterial elasticity, aiding in the diagnosis of vascular conditions, while the MD-3000 delivers precise insights into blood vessel diseases. Additionally, the HD/PulseWave CR-2000 is a specialized system designed for scientific research, allowing for non-intrusive evaluations of arterial elasticity. The devices capture 30 seconds of blood pressure waveform data and analyze it to generate comprehensive reports detailing metrics such as blood pressure, heart rate, and indices for large and small artery elasticity. HDII's clientele includes general practitioners, cardiologists, healthcare practitioners, academic researchers, and pharmaceutical companies, with U.S. sales supported by a dedicated network of representatives. Through its innovative approach, HDII positions itself as a critical player in the medical diagnostics landscape, addressing significant healthcare needs related to hypertension management.
What Products and Services Does HDII Offer?
- Design and develop non-invasive medical technologies for cardiovascular diagnostics.
- Manufacture the CVProfilor system for assessing arterial elasticity.
- Provide diagnostic tools that help in the early detection of cardiovascular diseases.
- Generate comprehensive reports detailing critical cardiovascular metrics.
- Serve a diverse clientele including healthcare practitioners and research scientists.
- Facilitate U.S. sales through a network of dedicated representatives.
How Does HDII Make Money?
- Generate revenue through the sale of medical diagnostic devices.
- Offer specialized products for both clinical and research applications.
- Leverage partnerships with healthcare providers and pharmaceutical companies.
- Focus on innovation to enhance product offerings and market competitiveness.
- Utilize a direct sales model to reach healthcare professionals effectively.
What Industry Does HDII Operate In?
The medical diagnostics industry is experiencing significant growth, driven by increasing awareness of cardiovascular diseases and the need for early detection methods. The global market for cardiovascular diagnostics is projected to expand at a compound annual growth rate (CAGR) of over 10% in the coming years, reflecting a rising demand for non-invasive solutions. Within this competitive landscape, Hypertension Diagnostics, Inc. (HDII) distinguishes itself with its specialized focus on arterial elasticity assessment, catering to a diverse range of clients from healthcare practitioners to academic researchers. The company’s innovative technologies position it well to capitalize on the growing trend towards preventive healthcare and early diagnosis.
Who Are HDII's Key Customers?
- General practitioners seeking non-invasive diagnostic tools.
- Cardiologists requiring precise assessments of arterial health.
- Healthcare practitioners in various specialties focused on cardiovascular care.
- Academic and government researchers conducting studies on cardiovascular health.
- Pharmaceutical companies involved in drug development and clinical trials.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Hypertension Diagnostics, Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Richmond Hill, CA. The company is led by CEO Liangjian Peng. HDII has traded publicly since 1998.
Financial Health
Hypertension Diagnostics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 6 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
HDII Financials
HDII Latest News
No recent news available for HDII.
HDII Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HDII.
Price Targets
Wall Street price target analysis for HDII.
HDII MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HDII; grades run from A+ (80-100) to F (below 30).
Leadership: Liangjian Peng
CEO
Liangjian Peng has been leading Hypertension Diagnostics, Inc. since its inception in 1988. With a strong background in medical technology and diagnostics, he has played a pivotal role in the company's development of innovative non-invasive medical devices. His leadership has been marked by a commitment to advancing cardiovascular health through technology.
Track Record: Under Liangjian Peng's leadership, HDII has successfully launched several key products, including the CVProfilor series, which have become essential tools in cardiovascular diagnostics. His strategic vision has positioned the company as a leader in non-invasive medical technology.
HDII OTC Market Information
The OTC Other tier represents companies that trade over-the-counter but do not meet the stringent requirements of the NYSE or NASDAQ. This tier often includes smaller companies with less regulatory oversight, which can lead to higher volatility and risks for investors.
- OTC Tier: OTC Other
- Limited regulatory oversight can lead to increased investment risks.
- Potential for lower trading volumes, resulting in liquidity challenges.
- Lack of financial transparency may hinder investor confidence.
- Market volatility can significantly affect stock performance.
- Verify the company's product certifications and regulatory approvals.
- Assess the financial health and operational capacity of HDII.
- Investigate the competitive landscape and market positioning.
- Review any partnerships or collaborations that may enhance growth.
- Monitor industry trends that could impact demand for HDII's products.
- Established history in the medical diagnostics sector since 1988.
- Innovative product offerings that address significant healthcare needs.
- Diverse clientele, including healthcare practitioners and researchers.
HDII Financials Stock FAQ
What are the main risks for HDII?
Hypertension Diagnostics, Inc. faces several risks, including limited regulatory oversight typical of OTC stocks, which may impact investor confidence. Additionally, the company operates in a competitive landscape where established players pose a threat to its market share. Economic fluctuations can also affect healthcare spending, impacting sales of HDII's products.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial data available due to OTC classification.